Hodgkin Lymphoma: Epidemiology Report and Forecast

Hodgkin Lymphoma: Epidemiology Report and Forecast

Summary

Hodgkin lymphoma (HL) is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. The exact cause of HL is unclear; however, 20-40% of HL cases had a prior diagnosis of infectious mononucleosis caused by the Epstein-Barr virus (EBV). HL originates from germinal center or post-germinal B cells, which can mutate, causing rapid division of the cells and forming abnormal giant B-cells known as Reed-Sternberg cells (Gopas et al., 2016; Munir et al., 2023).

HL is classified into two main groups—classical Hodgkin lymphoma (cHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). cHL is further divided into subtypes, namely nodular sclerosis (NS), mixed cellularity (MC), lymphocyte-rich (LR), lymphocyte-depleted (LD), and unspecified cells. The classical form is the most frequently occurring HL, with almost 95% of HL cases belonging to the cHL type (Cancer Research UK, 2023). The most common symptoms of HL include enlarged lymph nodes under the skin of the neck, under the arm, or in the groin; fever (which can come and go over several days or weeks) without an infection; drenching night sweats; and weight loss (Munir et al., 2023).

In the 8MM, the analyst epidemiologists forecast the diagnosed incident cases of cHL from 26,902 cases in 2025 to 27,745 cases by 2035, at an Annual Growth Rate (AGR) of 0.31%. The US will have the highest number of cHL cases throughout the forecast period, representing 30.86% of cases in the 8MM in 2025. The five-year diagnosed prevalent cases of cHL in the 8MM are also expected to increase 114,416 cases in 2025 to 119,238 cases by 2035, at an AGR of 0.42%.

Scope

• The Hodgkin lymphoma Epidemiology Report and Forecast provide an overview of the risk factors, comorbidities, and global trends of Hodgkin lymphoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
• The report includes a 10-year epidemiology forecast of the active diagnosed incident cases of Hodgkin lymphoma in these markets from 2025-35. The active diagnosed incident cases are further segmented by sex and age (ranging from age 0 years to ages 85 years and older). The active diagnosed incident cases are further segmented by stage at diagnosis, histological subtype, relapse status and mutational status. This report also provides the 5-year diagnosed prevalent cases of Hodgkin lymphoma for both sexes and all ages.

Reasons to Buy

• The Hodgkin lymphoma Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global Hodgkin lymphoma markets.
• Quantify patient populations in the global Hodgkin lymphoma markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hodgkin lymphoma therapeutics in each of the markets covered.
• Understand magnitude of the active diagnosed Hodgkin lymphoma population by age, sex, stage at diagnosis, histological subtype, and relapse and mutational status.